187 related articles for article (PubMed ID: 23666879)
1. A toxicity risk index, an index for warning idiosyncratic drug toxicity.
Morimoto M; Samizo K; Ohta S; Mizuma T
J Pharm Sci; 2013 Sep; 102(9):3447-50. PubMed ID: 23666879
[TBL] [Abstract][Full Text] [Related]
2. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding.
Nakayama S; Atsumi R; Takakusa H; Kobayashi Y; Kurihara A; Nagai Y; Nakai D; Okazaki O
Drug Metab Dispos; 2009 Sep; 37(9):1970-7. PubMed ID: 19487250
[TBL] [Abstract][Full Text] [Related]
3. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
[TBL] [Abstract][Full Text] [Related]
4. Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide.
Sawamura R; Okudaira N; Watanabe K; Murai T; Kobayashi Y; Tachibana M; Ohnuki T; Masuda K; Honma H; Kurihara A; Okazaki O
Drug Metab Dispos; 2010 Oct; 38(10):1857-64. PubMed ID: 20606003
[TBL] [Abstract][Full Text] [Related]
5. Idiosyncratic toxicity: a convergence of risk factors.
Ulrich RG
Annu Rev Med; 2007; 58():17-34. PubMed ID: 16958561
[TBL] [Abstract][Full Text] [Related]
6. A Survey of Neonatal Pharmacokinetic and Pharmacodynamic Studies in Pediatric Drug Development.
Wang J; Avant D; Green D; Seo S; Fisher J; Mulberg AE; McCune SK; Burckart GJ
Clin Pharmacol Ther; 2015 Sep; 98(3):328-35. PubMed ID: 25975723
[TBL] [Abstract][Full Text] [Related]
7. Prediction of black box warning by mining patterns of Convergent Focus Shift in clinical trial study populations using linked public data.
Ma H; Weng C
J Biomed Inform; 2016 Apr; 60():132-44. PubMed ID: 26851401
[TBL] [Abstract][Full Text] [Related]
8. In vitro cytotoxicity assay to evaluate the toxicity of an electrophilic reactive metabolite using glutathione-depleted rat primary cultured hepatocytes.
Fujimoto K; Kishino H; Yamoto T; Manabe S; Sanbuissho A
Chem Biol Interact; 2010 Dec; 188(3):404-11. PubMed ID: 20846519
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of the potential for drug-induced toxicity based on (35)S-labeled glutathione adduct formation and daily dose.
Miyaji Y; Makino C; Kurihara A; Suzuki W; Okazaki O
Bioanalysis; 2012 Feb; 4(3):263-9. PubMed ID: 22303830
[TBL] [Abstract][Full Text] [Related]
10. Predicting toxicities of reactive metabolite-positive drug candidates.
Kalgutkar AS; Dalvie D
Annu Rev Pharmacol Toxicol; 2015; 55():35-54. PubMed ID: 25292426
[TBL] [Abstract][Full Text] [Related]
11. Computational chemistry approach for the early detection of drug-induced idiosyncratic liver toxicity.
Cruz-Monteagudo M; Cordeiro MN; Borges F
J Comput Chem; 2008 Mar; 29(4):533-49. PubMed ID: 17705164
[TBL] [Abstract][Full Text] [Related]
12. Detecting reactive drug metabolites for reducing the potential for drug toxicity.
Grillo MP
Expert Opin Drug Metab Toxicol; 2015; 11(8):1281-302. PubMed ID: 26005795
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450s and other enzymes in drug metabolism and toxicity.
Guengerich FP
AAPS J; 2006 Mar; 8(1):E101-11. PubMed ID: 16584116
[TBL] [Abstract][Full Text] [Related]
14. Differences between pharmacokinetics and toxicokinetics.
Welling PG
Toxicol Pathol; 1995; 23(2):143-7. PubMed ID: 7569668
[TBL] [Abstract][Full Text] [Related]
15. [FOOD - DRUG INTERACTIONS: TYPES AND MECHANISMS.].
Lemina EY; Churyukanov VV
Eksp Klin Farmakol; 2016; 79(11):41-44. PubMed ID: 29791108
[TBL] [Abstract][Full Text] [Related]
16. Idiosyncratic toxicity: the role of toxicophores and bioactivation.
Williams DP; Park BK
Drug Discov Today; 2003 Nov; 8(22):1044-50. PubMed ID: 14690635
[TBL] [Abstract][Full Text] [Related]
17. Role of metabolism in drug-induced idiosyncratic hepatotoxicity.
Walgren JL; Mitchell MD; Thompson DC
Crit Rev Toxicol; 2005; 35(4):325-61. PubMed ID: 15989140
[TBL] [Abstract][Full Text] [Related]
18. Should the incorporation of structural alerts be restricted in drug design? An analysis of structure-toxicity trends with aniline-based drugs.
Kalgutkar AS
Curr Med Chem; 2015; 22(4):438-64. PubMed ID: 25388012
[TBL] [Abstract][Full Text] [Related]
19. Relationship between the risk of idiosyncratic drug toxicity and formation and degradation profiles of acyl-glucuronide metabolites of nonsteroidal anti-inflammatory drugs in rat liver microsomes.
Shimada H; Ikuta H; Kumazawa K; Nomi M; Shiojiri M; Kawase A; Iwaki M
Eur J Pharm Sci; 2022 Jul; 174():106193. PubMed ID: 35447304
[TBL] [Abstract][Full Text] [Related]
20. Drugs in control samples in nonclinical safety studies: a reconsideration.
Zimmer D
Bioanalysis; 2016 May; 8(10):1003-7. PubMed ID: 27080047
[No Abstract] [Full Text] [Related]
[Next] [New Search]
